IRON - Wutah pendapatan taunan sajrone rolas wulan kepungkur Disc Medicine, Inc.

Logo perusahaan publik Disc Medicine, Inc. (IRON)

Disc Medicine, Inc. (IRON) focuses on the development of bitopertin for the treatment of porphyria, awaiting FDA approval and potential M&A deals. A team of hematology experts strives for scientific breakthroughs, driven by stock option incentives. The rolling annual revenue growth from sales visualizes income dynamics, where 0.00 reflects the metric's baseline. However, high research and development costs are depleting the company's capital.

Wutah dodolan YoY (TTM): Disc Medicine Corp (IRON) kanggo 11.02.2024 - 18.11.2026

Ringkesan rincian data analitis Disc Medicine Inc (IRON)

- rega saham lan prakiraan rega para ahli:
Ringkesan analitik perusahaan:Disc Medicine, Inc.
Produk merek Disc Medicine

Disc Medicine, Inc. maintains its status as a leader in the development of innovative therapies for hematological blood diseases. By analyzing the year-over-year sales trend over a 12-month period, an investor can observe the rolling year revenue dynamics. The current value of 0.00 reflects the percentage growth in revenue relative to the same window from the previous year. This indicator confirms the operational efficiency and the stability of the market positions of this highly reputable biotechnology brand.